AlzeCure is organized as a foundation, initially based on donations and grants from individuals, non-profit organizations and governments. This organization form provides stability for continuous evaluation of novel concepts from academic or industrial research, but is combined with the overall aim of AlzeCure to commercialize its successful projects.A large body of evidence suggests that loss of nerve growth factor (NGF) signaling contributes significantly to the dysfunction of the brain in patients with Alzheimer's disease. There are numerous studies performed in animal models of Alzheimer's disease and other disorders that strongly suggest that also brain derived neurotrophic factor (BDNF) signaling mediate function of nerve cells. Inspired by the important role of NGF and BDNF and the huge unmet medical need in Alzheimer's disease, we have identified small molecules that enhance NGF and BDNF signaling. To this end we have identified several different series of compounds. These molecules act as positive modulators of the signaling of NGF and BDNF and appear to be selective versus the closely related tyrosine kinase receptor IGF1R . We are currently progressing our lead series in a medicinal chemistry effort, which has improved potency of the original compounds more than 20-fold. We think that these compounds, in combination with an exciting and potentially very beneficial pharmacological profile, may indeed mediate neurorestorative as well as cognitive effects in patients with Alzheimer's disease.